Viome, GSK to develop cancer, autoimmune disease therapies

By The Science Advisory Board staff writers

October 20, 2021 -- Viome Life Sciences has expanded its partnership with GlaxoSmithKline (GSK) to develop potential therapies for cancer and autoimmune diseases.

Through the collaboration, Viome and GSK will examine the connection between the gut microbiome and the onset of specific chronic disorders. The companies will explore therapies using targets based on Viome's discovery platform, which analyzes host and microbial interaction at the onset and progression of diseases.

GSK to establish new life science campus in U.K.
GlaxoSmithKline (GSK) has announced plans to develop a more than 1 million-sq-ft life science campus research and development campus in Stevenage,...
Sanofi, GSK initiate phase III trial of COVID-19 vaccine
Sanofi and GlaxoSmithKline started their phase III trial to assess the safety, efficacy, and immunogenicity of their recombinant-protein COVID-19 vaccine...
EMA gives positive nod to GSK, Vir COVID-19 mAb
GlaxoSmithKline (GSK) and Vir Biotechnology today announced that the European Medicines Agency's (EMA) Committee for Human Medicinal Products has issued...
Sanofi, GSK COVID-19 vaccine to advance to phase III trials
Sanofi and GlaxoSmithKline's (GSK's) adjuvanted, recombinant COVID-19 vaccine candidate produced strong rates of neutralizing antibody responses in all...
EMA to review GSK, Vir COVID-19 mAb
GlaxoSmithKline (GSK) and Vir Biotechnology announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter